Risks of Oral Anticoagulant Therapy With Increasing Age

Managing oral anticoagulant therapy.

2001;119;22S-38S Chest Leon Poller, Alan Jacobson, Daniel Deykin and David Matchar Jack Ansell, Jack Hirsh, James Dalen, Henry Bussey, David Anderson, Managing Oral Anticoagulant Therapy l.html http://chestjournal.chestpubs.org/content/119/1_suppl/22S.ful and services can be found online on the World Wide Web at: The online version of this article, along with updated information ISSN:0012-3692 ...

Oral Anticoagulant Therapy

on laboratory and clinical monitoring and on reversal strategies. More recently, new oral anticoagulant drugs, namely the direct thrombin inhibitor dabigatran etexilate and the direct factor Xa inhibitor rivaroxaban, have been approved for clinical use in several countries. A growing body of laboratory and clinical data is becoming available to better understand the mechanisms of action and the...

Oral anticoagulant therapies: balancing the risks.

PURPOSE To describe the mechanisms of action, pharmacokinetics, and rate of bleeding complications from warfarin and target-specific oral anticoagulants; methods for assessing the risk for thromboembolism and bleeding in patients receiving oral anticoagulants or temporarily interrupting such therapy to undergo elective invasive procedures or surgery; therapeutic strategies for balancing these r...

Pharmacogenetics of oral anticoagulant therapy

Pharmacogenetics of oral anticoagulant therapy

Introduction In the last 70 years the antagonists of vitamin K (AVK) were the only therapeutic solution for oral anticoagulation in primary and secondary prophylaxis of arterial and venous thrombosis. The utility of AVK was demonstrated in many situations and presently they are taken by millions patients in the entire world. Many clinical and lab studies contributed to understanding of AVKs’ ph...